Related Experiment Video

Updated: May 19, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Pertuzumab: new hope for patients with HER2-positive breast cancer

M Capelan1, L Pugliano2, E De Azambuja1

  • 1Department of Medicine, Institute Jules Bordet, L'Université Libre de Bruxelles, Brussels; BrEAST Data Center, Institute Jules Bordet, l'Université Libre de Bruxelles, Brussels.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|August 23, 2012
PubMed
Abstract

Insights

Pertuzumab combined with trastuzumab offers a new dual blockade therapy for HER2-positive breast cancer (BC). This approach improves disease-free survival and represents a significant advance in personalized medicine for BC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Human epidermal growth factor receptor 2 (HER2) overexpression occurs in 15-20% of breast cancers (BCs).
  • Trastuzumab therapy revolutionized prognosis for HER2-positive BC but faces resistance.
  • Pertuzumab is a novel anti-HER2 antibody inhibiting HER2 dimerization, addressing resistance to trastuzumab.

Purpose of the Study:

  • To describe pertuzumab's mechanism of action, safety, and clinical role in HER2-positive BC.
  • To explore pertuzumab's efficacy as a single agent and in combination with trastuzumab.
  • To review preclinical and clinical trial data on pertuzumab in HER2-positive BC.

Main Methods:

  • Computer-based literature search using PubMed (keywords: breast neoplasm, dimerization, HER-2, pertuzumab).
  • Inclusion of data presented at international meetings.
  • Review of preclinical research and ongoing clinical trials, including the CLEOPATRA study.

Main Results:

  • Pertuzumab demonstrates efficacy and tolerability in HER2-positive BC.
  • Combination therapy with pertuzumab and trastuzumab significantly increases disease-free survival.
  • The CLEOPATRA study highlights the benefits of this dual blockade approach.

Conclusions:

  • Dual blockade with pertuzumab and trastuzumab is a substantial advance for HER2-positive BC patients.
  • This combination therapy represents a new milestone in personalized medicine for breast cancer.
  • Pertuzumab offers a complementary mechanism to trastuzumab, overcoming resistance.

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...